Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J-L Teo

Showing results (1-10 of 3) with videos related to

Pageof 1
Sort By:
JDR Clinical and Translational Research|March 8, 2023
Exploring Oral Function, Protein Intake, and Risk of Sarcopenia: A Scoping ReviewP J Moynihan, J-L Teo
Oncogene|December 15, 2015
CBP/catenin antagonist safely eliminates drug-resistant leukemia-initiating cellsY Zhao, D Masiello, M McMillian, et al.
The Pharmacogenomics Journal|January 11, 2012
Pharmacogenetic profiling of CD133 is associated with response rate (RR) and progression-free survival (PFS) in patients with metastatic colorectal cancer (mCRC), treated with bevacizumab-based chemotherapyA Pohl, A El-Khoueiry, D Yang, et al.
Pageof 1

Showing results (1-10 of 3) with videos related to

Sort By:
Pageof 1
JDR Clinical and Translational Research|March 8, 2023
Exploring Oral Function, Protein Intake, and Risk of Sarcopenia: A Scoping ReviewP J Moynihan, J-L Teo
Oncogene|December 15, 2015
CBP/catenin antagonist safely eliminates drug-resistant leukemia-initiating cellsY Zhao, D Masiello, M McMillian, et al.
The Pharmacogenomics Journal|January 11, 2012
Pharmacogenetic profiling of CD133 is associated with response rate (RR) and progression-free survival (PFS) in patients with metastatic colorectal cancer (mCRC), treated with bevacizumab-based chemotherapyA Pohl, A El-Khoueiry, D Yang, et al.
Pageof 1